Bellevue Group AG Boosts Stake in Ascendis Pharma A/S $ASND

Bellevue Group AG increased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 1,408.2% during the second quarter, HoldingsChannel reports. The firm owned 28,655 shares of the biotechnology company’s stock after buying an additional 26,755 shares during the period. Bellevue Group AG’s holdings in Ascendis Pharma A/S were worth $4,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Compagnie Lombard Odier SCmA bought a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $39,000. First Horizon Advisors Inc. bought a new stake in shares of Ascendis Pharma A/S in the second quarter worth approximately $41,000. Brooklyn Investment Group raised its holdings in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the last quarter. Hantz Financial Services Inc. lifted its position in Ascendis Pharma A/S by 291.1% during the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the period. Finally, LVW Advisors LLC purchased a new stake in Ascendis Pharma A/S in the second quarter worth approximately $202,000.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $220.42 on Friday. The business’s fifty day moving average is $206.34 and its 200 day moving average is $191.13. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $229.94. The company has a market capitalization of $13.60 billion, a PE ratio of -49.64 and a beta of 0.45.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $250.71 million during the quarter, compared to analysts’ expectations of $246.91 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ASND shares. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research note on Thursday. Bank of America upped their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Wedbush restated an “outperform” rating and set a $220.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, November 18th. Finally, Wall Street Zen lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus target price of $256.73.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.